论文部分内容阅读
目的观察和分析氨溴索联合布地奈德治疗新生儿感染性肺炎的临床疗效。方法 100例新生儿感染肺炎患者,随机分为治疗组和对照组,各50例,治疗组给予氨溴索联合布地奈德雾化吸入,对照组给予地塞米松联合糜蛋白酶雾化吸入。治疗前后对两组患者的肺功能进行检查,观察并记录两组患儿的临床疗效。结果治疗前,两组患儿肺功能比较,差异无统计学意义(P>0.05);治疗后两组患者的肺功能较治疗前均具有明显的改善,差异具有统计学意义(P<0.05);且治疗组肺功能的改善情况优于对照组,差异具有统计学意义(P<0.05);治疗组的总有效率92%明显高于对照组的84%,差异具有统计学意义(P<0.05)。结论氨溴索联合布地奈德治疗新生儿感染性肺炎的临床效果较好。
Objective To observe and analyze the clinical efficacy of ambroxol combined with budesonide in the treatment of neonatal pneumonia. Methods 100 cases of neonates with pneumonia were randomly divided into treatment group and control group, 50 cases in each group. The treatment group was given inhalation of ambroxol combined with budesonide. The control group was given dexamethasone combined with chymotrypsin inhalation. Before and after treatment of lung function of two groups of patients were examined to observe and record the clinical efficacy of two groups of children. Results Before treatment, there was no significant difference in lung function between the two groups (P> 0.05). After treatment, the lung function of the two groups was significantly improved compared with that before treatment, with significant difference (P <0.05) (P <0.05). The total effective rate in the treatment group was significantly higher than that in the control group (92%) (P <0.05), and the improvement of pulmonary function in the treatment group was better than that in the control group 0.05). Conclusion Ambroxol combined with budesonide is effective in treating neonatal pneumonia.